Abstract
Objective: To further investigate the role of prior medical conditions and medication use in the etiology of non-Hodgkin lymphoma (NHL), we analyzed the data from a population-based case–control study of NHL in Connecticut women.
Methods: A total of 601 histologically confirmed incident cases of NHL and 717 population-based controls were included in this study. In-person interviews were administered using standardized, structured questionnaires to collect information on medical conditions and medication use.
Results: An increased risk was found among women who had a history of autoimmune disorders (such as rheumatoid arthritis, lupus erythematosus, Sjogren's syndrome, and multiple sclerosis), anemia, eczema, or psoriasis. An increased risk was also observed among women who had used steroidal anti-inflammatory drugs and tranquilizers. A reduced risk was found for women who had scarlet fever or who had used estrogen replacement therapy, aspirin, medications for non-insulin dependent diabetes, HMG-CoA reductase inhibitors, or beta-adrenergic blocking agents. Risk associated with past medical history appeared to vary based on NHL subtypes, but the results were based on small number of exposed subjects.
Conclusion: A relationship between certain prior medical conditions and medication use and risk of NHL was observed in this study. Further studies are warranted to confirm our findings.
Similar content being viewed by others
References
Zheng T, Mayne ST, Boyle P, et al. (1992) Epidemiology of non-Hodgkin's lymphomas in Connecticut, 1935-1988. Cancer 70: 840–849.
Hartge P, Devesa SS, Fraumeni Jr JF (1994) Hodgkin's and Non-Hodgkin's Lymphomas. Cancer Surv 19/20: 423–453.
Isomaki H, Hakulinen T, Joutsenlahti U (1979) Lymphoma and rheumatoid arthritis. Lancet 1: 392–¦.
Gridley G, McLaughlin JK, Ekbom A, et al. (1993) Incidence of cancer among patients with rheumatoid arthritis. J Natl Cancer Inst 85: 307–311.
Mellemkjaer L, Linet G, Gridley M, Frisch M, Moller H, Olsen JH (1996) Rheumatoid arthritis and cancer risk. Eur J Cancer 32A: 1753–1757.
Thomas E, Brewster DH, Black R, Macfarlane GJ (2000) Risk of malignancy among patients with rheumatic conditions. Int J Cancer 88: 497–502.
Tavani A, La Vecchia C, Franceschi S, Serraino D, Carbone A (2000) Medical history and risk of Hodgkin's and non-Hodgkin's lymphomas. Eur J Cancer Prev 9: 59–64.
Kassan SS, Thomas TL, Moutsopoulos HM, et al. (1978) Increased risk of lymphoma in sicca syndrome. Ann Int Med 89: 888–892.
Bernard SM, Cartwright RA, Bird CC, Richards G, Lauder I, Roberts BE (1984) Aetiologic factors in lymphoid malignances: a case-control epidemiological study. Leuk Res 8: 681–689.
Cotelingam JD, Witebsky FG, Hsu SM, Blaese RM, Jaffe ES (1985) Malignant lymphoma in patients with the Wiskott-Aldrich syndrome. Cancer Invest 3: 515–522.
Cartwright RA, McKinney PA, O'Brien C, et al. (1988) Non-Hodgkin's lymphoma: case control epidemiological study in Yorkshire. Leuk Res 12: 81–88.
Doody MM, Linet MS, Glass AG, et al. (1992) Leukemia, lymphoma, and multiple myeloma following selected medical conditions. Cancer Causes Control 3: 449–456.
Bernstein L, Ross RK (1992) Prior medication use and health history as risk factors for non-Hodgkin's lymphoma: preliminary results from a case-control study in Los Angeles county. Cancer Res 52: 5510s–5515s.
Arellano F (1997) Risk of cancer with cyclosporine in psoriasis. Int J Dermatol 36(Suppl. 1): 15–17.
Hannuksela-Svahn A, Pukkala E, Laara E, Poikolainen K, Karvonen J (2000) Psoriasis, its treatment, and cancer in a cohort of Finnish patients. J Invest Dermatol 114: 587–590.
Morales MM, Olsen J, Johansen P, et al. (2003) Viral infection, atopy and mycosis fungoides: a European multicentre case-control study. Eur J Cancer 39: 511–516.
Frentz G, Olsen JH (1999) Malignant tumours and psoriasis: a follow-up study. Br J Dermatol 140: 237–242.
Boffetta P, Gridley G, Lindelof B (2001) Cancer risk in a population-based cohort of patients hospitalized for psoriasis in Sweden. J Invest Dermatol 117: 1531–1537.
Cerhan JR, Vachon CM, Habermann TM, et al. (2002) Hormone replacement therapy and risk of non-Hodgkin lymphoma and chronic lymphocytic leukemia. Cancer Epidemiol Biomark Prev 11: 1466–1471.
Cerhan JR, Wallace RB, Folsom AR, et al. (1997) Medical history risk factors for non-Hodgkin's lymphoma in older women. J Natl Cancer Inst 89: 314–318.
Vena JE, Bona JR, Byers TE, Middleton E, Swanson MK, Graham S (1985) Allergy-related diseases and cancer: an inverse association. Am J Epidemiol 122: 66–74.
McWhorter WP (1988) Allergy and risk of cancer. A prospective study using NHANESI followup data. Cancer 62: 451–455.
Nelson RA, Levine AM, Bernstein L (2001) Reproductive factors and risk of intermediate-or high-grade B-cell non-Hodgkin's lymphoma. J Clin Oncol 19: 1381–1387.
Anthony JJ (1970) Malignant lymphoma associated with hydantoin drugs. Arch Neurol 22: 450–454.
Li FP, Willard DR, Goodman R, Vawter G (1975) Malignant lymphoma after diphenylhydantoin (dilantin) therapy. Cancer 36: 1359–1362.
White SJ, McLean AEM, Howland C (1979) Anticonvulsant drugs and cancer. A cohort study in patients with severe epilepsy. Lancet 2: 458–461.
Shirts SB, Annegers JF, Hauser WA, Kurland LT (1986) Cancer incidence in a cohort of patients with seizure disorders. J Natl Cancer Inst 77: 83–87.
Olsen JH, Boice JD, Jensen JPA, Fraumeni JF (1989) Cancer among epileptic patients exposed to anticonvulsant drugs. J Natl Cancer Inst 81: 803–808.
Rosenberg L, Palmer JR, Zauber AG, et al. (1995) Relation of benzodiazepine use to the risk of selected cancers: breast, large bowel, malignant melanoma, lung, endometrium, ovary, non-Hodgkin's lymphoma, testis, Hodgkin's disease, thyroid, and liver. Am J Epidemiol 141: 1153–1160.
Herrinton L (1998) Epidemiology of the Revised European-American Lymphoma classification subtypes. Epidemiol Rev 20: 187–203.
World Health Organization (1990) International Classification of Disease for Oncology, 2nd edn. Geneva, Switzerland: World Health Organization.
Kauppi M, Pukkala E, Isomaki H (1997) Elevated incidence of hematologic malignancies in patients with Sjogren's syndrome compared with patients with rheumatoid arthritis (Finland). Cancer Causes Control 8: 201–204.
Baecklund E, Ekbom A, Sparen P, Feltelius N, Klareskog L (1998) Disease activity and risk of lymphoma in patients with rheumatoid arthritis: nested case-control study. BMJ 317: 180–181.
Rosenthal AK, McLaughlin JK, Gridley G, Nyren O (1995) Incidence of cancer among patients with systemic sclerosis. Cancer 76: 910–914.
Amann U, Mielke V, Metze D, Bonsmann G, Schwarz T (1995) Perioral eczema as a manifestation of cutaneous T-cell lymphoma. Br J Dermatol 132: 671–673.
Elmer KB, George RM (1999) Cutaneous T-cell lymphoma presenting as benign dermatoses. Am Fam Physician 59: 2809–2813.
Sonoki T, Matsuzaki H, Asou N, et al. (1996) Aggressive CD5-positive di.use large B cell lymphoma showing c-myc rearrangements developed in a patient with autoimmune hemolytic anemia. Int J Hematol 63: 71–76.
Jameel T, Anwar M, Abdi SI, Saleem M, Ahmad PA, Khattak MF (1997) Aplastic anemia or aplastic preleukemic syndrome? Ann Hematol 75: 189–193.
Beiderbeck AB, Holly EA, Sturkenboom MC, Coebergh JW, Stricker BH, Leufkens HG (2003) No increased risk of non-Hodgkin's lymphoma with steroids, estrogens and psychotropics (Netherlands). Cancer Causes Control 14: 639–644.
Cerhan JR, Habermann TM, Vachon CM, et al. (2002) Menstrual and reproductive factors and risk of non-Hodgkin lymphoma: the Iowa women's health study (United States). Cancer Causes Control 13: 131–136.
Adami HO, Tsaih S, Lambe M, et al. (1997) Pregnancy and risk of non-Hodgkin's lymphoma: a prospective study [erratum appears in Int J Cancer 1997 May 16; 71(4): 705]. Int J Cancer 70: 155–158.
Zheng T, Zhang Y, Morton L, Zhu Y (in press) Re: No increased risk of non-Hodgkin's lymphoma with steroids, estrogens and psychotropics (Netherlands) Cancer Causes Control.
Jilka RL, Hangoc G, Girasole G, et al. (1992) Increased osteoclast development after estrogen loss: Mediation by interleukin-6. Science 257: 88–91.
Cheleuitte D, Mizuno S, Glowacki J (1998) in vitro secretion of cytokines by human bone marrow: Effects of age and estrogen status. J Clin Endocrinol Metab 83: 2043–2051.
Girasole G, Jilka RL, Passeri G, et al. (1992) 17 beta-estradiol inhibits interleukin-6 production by bone marrow-derived stromal cells and osteoblasts in vitro: A potential mechanism for the antiosteoporotic effect of estrogens. J Clin Invest 89: 883–891.
Saucedo R, Rico G, Basurto L, Ochoa R, Zarate A (2002) Transdermal estradiol in menopausal women depresses interleukin-6 without affecting other markers of immune response. Gynecol Obstetric Invest 53: 114–117.
Rachon D, MySliwska J, Suchecka-Rachon K, Wieckiewicz J, MySliwski A (2002) Effects of oestrogen deprivation on interleukin-6 production by peripheral blood mononuclear cells of postmenopausal women. J Endocrinol 172: 387–395.
Rogers A, Eastell R (2001) The effect of 17beta-estradiol on production of cytokines in cultures of peripheral blood. Bone 29: 30–34.
Tabibzadeh SS, Santhanam U, Sehgal PB, May LT (1989) Cytokine-induced production of IFN-beta 2/IL-6 by freshly explanted human endometrial stromal cells. Modulation by estradiol-17 beta. J Immunol 142: 3134–3139.
Preti HA, Cabanillas F, Talpaz M, Tucker SL, Seymour JF, Kurzrock R (1997) Prognostic value of serum interleukin-6 in diffuse large-cell lymphoma [comment]. Ann Intern Med 127: 186–194.
Doody MM, Linet MS, Glass AG, et al. (1996) Risks of non-Hodgkin's lymphoma, multiple myeloma, and Leukemia associated with common medications. Epidemiology 7: 131–139.
Kato I, Koenig KL, Shore RE, et al. (2002) Use of anti-inflammatory and non-narcotic analgesic drugs and risk of non-Hodgkin's lymphoma (NHL) (United States). Cancer Causes Control 13: 965–974.
Holly EA, Lele C, Bracci PM, McGrath MS (1999) Case-control study of non-Hodgkin's lymphoma among women and heterosexual men in the San Francisco Bay Area, California. Am J Epidemiol 150: 375–389.
Cerhan JR, Anderson KE, Janney CA, Vachon CM, Witzig TE, Habermann TM (2003) Association of aspirin and other non-steroidal anti-inflammatory drug use with incidence of non-Hodgkin lymphoma. Int J Cancer 106: 784–788.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Zhang, Y., Holford, T.R., Leaderer, B. et al. Prior Medical Conditions and Medication use and Risk of non-Hodgkin lymphoma in Connecticut United States Women. Cancer Causes Control 15, 419–428 (2004). https://doi.org/10.1023/B:CACO.0000027506.55846.5d
Issue Date:
DOI: https://doi.org/10.1023/B:CACO.0000027506.55846.5d